Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma

Cancer
Wen-Jen HwuAlan N Houghton

Abstract

Temozolomide and interferon-alpha-2b (IFN-alpha-2b) are both active in melanoma. Therefore, the efficacy and safety of temozolomide in combination with pegylated IFN-alpha-2b in patients with metastatic melanoma without brain metastases was investigated. Patients with histologically confirmed, unresectable, American Joint Committee on Cancer Stage IV melanoma were enrolled in an open-label, Phase II study. The primary endpoints were tumor response and safety. Patients received temozolomide (75 mg/m2/dayx6 weeks with a 2-week break between cycles) plus concomitant subcutaneous pegylated IFN-alpha-2b (0.5 microg/kg/wk, continuously). Treatment was continued until unacceptable toxicity or disease progression occurred. Thirty-five patients (median age, 55 years) with Stage IV melanoma and a median of 3 metastatic sites were enrolled and received a median of 1 cycle (i.e., 8 weeks) of therapy (range, 0-6 cycles). Eleven patients (31%) (95% confidence interval, 16% to 47%) had an objective tumor response, including 3 with clinical complete response durations of 6 months, 20 months, and 32+ months and 8 with partial responses. Three patients with a partial or mixed response were subsequently rendered free of clinically detectable dise...Continue Reading

References

Nov 1, 1983·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J R AndersonR D Gelber
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M B AtkinsS A Rosenberg
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M R MiddletonN Thatcher
Nov 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J ManolaJ Kirkwood
Aug 2, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·K L LindsayUNKNOWN Hepatitis Interventional Therapy Group
Aug 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C M BalchJ F Thompson
Jul 13, 2002·Expert Review of Anticancer Therapy·S J Danson, M R Middleton
Sep 14, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ronald BukowskiCraig L Tendler
Mar 18, 2003·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Joseph A BauerDaniel J Lindner
Jun 28, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S DansonM R Middleton
Aug 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wen-Jen HwuAlan N Houghton
Jul 24, 2004·The British Journal of Dermatology·E RichtigJ Smolle
Sep 3, 2004·The New England Journal of Medicine·Hensin TsaoArthur J Sober
Jan 22, 2005·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun

❮ Previous
Next ❯

Citations

Aug 26, 2009·International Journal of Clinical Oncology·Tobias Walbert, Mark R Gilbert
Mar 12, 2008·Apoptosis : an International Journal on Programmed Cell Death·Shaun Rosebeck, Douglas W Leaman
Aug 16, 2008·Molecular BioSystems·Paul BrennanSaman Hewamana
Apr 30, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R von MoosUNKNOWN Swiss Group for Clinical Cancer Research (SAKK)
Sep 26, 2007·Anti-cancer Drugs·Ulka N VaishampayanLawrence E Flaherty
Feb 3, 2007·Current Opinion in Oncology·Jedd D Wolchok, Yvonne M Saenger
Feb 3, 2011·World Journal of Surgical Oncology·Umair KhalidMuhammad Rizwan Khan
Jul 5, 2007·Neurosurgical Focus·Robert Cavaliere, David Schiff
May 20, 2009·Future Oncology·Aaron S Mansfield, Svetomir N Markovic
Mar 28, 2013·Journal of Skin Cancer·Farid Menaa
Aug 27, 2009·Biologics : Targets & Therapy·Reinhard Dummer, Joanna Mangana
Nov 3, 2006·Expert Review of Neurotherapeutics·Jan Drappatz, Patrick Y Wen
Nov 17, 2009·Clinics in Plastic Surgery·Jonathan Treisman, Nina Garlie
Aug 13, 2009·Advanced Drug Delivery Reviews·Gianfranco Pasut, Francesco M Veronese
Oct 18, 2008·The Journal of Investigative Dermatology·Lei FangSam T Hwang
Dec 18, 2007·Seminars in Oncology·Hussein A Tawbi, John M Kirkwood
Jul 14, 2010·International Journal of Dermatology·Ettore Minutilli
May 26, 2009·Hematology/oncology Clinics of North America·Arvin S Yang, Paul B Chapman
Jun 16, 2015·Journal of Surgical Oncology·Alexandre DoussotT Peter Kingham
Feb 22, 2012·Oral Oncology·Chuan-Zheng SunMing Song
Jun 17, 2015·BioMed Research International·Roberta Balansin RigonMarlus Chorilli
May 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Petra RietschelPaul B Chapman
Feb 3, 2016·F1000Research·Martin L AshdownBrendon J Coventry
Mar 14, 2019·International Journal of Oncology·Kotaro MakitaAtsuo Yoshino
Oct 15, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ronald S GoJohn M Kirkwood
Jan 21, 2021·Cancers·Jawad FaresMaciej S Lesniak

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.